13 operations-"https:"-"https:"-"https:"-"https:"-"https:"-"https:"-"https:"-"https:"-"UCL" PhD positions at Amsterdam UMC
-
emerging from other POLARIS work packages. By aligning preclinical readouts with clinically relevant endpoints, your work will contribute to the translational value of leukodystrophy models. You will work
-
expertise. Together, we work towards improving our understanding of neurodegenerative diseases and ultimately contributing to better patient care. Amsterdam UMC Research BV Amsterdam UMC Research BV supports
-
embedded within the Quantitative Healthcare Analysis (qurAI) group and conducted in close collaboration with the CARA Lab and clinical partners in the Netherlands and abroad. You will work with large, multi
-
through to preclinical characterisation. Your work will include: Selecting GPRC5B-targeting nanobodies from immune and synthetic nanobody libraries and evaluating AI-generated candidates. Characterising
-
Hospital Tübingen (Eberhard Karls University of Tübingen), Germany. You will be embedded in the POLARIS consortium and work with experts in leukodystrophy, paediatric neurology, developmental psychopathology
-
of liquid biomarkers for leukodystrophies. You will work with iPSC-derived disease models and patient samples, generate and analyse multi-omics data, and help identify biomarkers that can support diagnosis
-
and its potential as a therapeutic target. Your work will include: Developing cell-based bioluminescent and fluorescent biosensor assays to detect GPCR signalling events in different cellular models
-
for identifying drug repurposing candidates. You will contribute to different stages of the research project. Your work will include: Developing and using human in vitro models derived from patient and control
-
is the Medicines Evaluation Board (MEB) in Utrecht, the Netherlands. You will be employed by the MEB and embedded in the POLARIS consortium. You will be supervised by Dr Marjon Pasmooij and work
-
will contribute to the development and evaluation of gene therapy approaches for PMLD1. Your work includes: establishing and using isogenic iPSC-derived myelinating organoids as a human in vitro disease